Drug‐induced dermatomyositis after zoledronic acid

Tong, Philip L.; Yu, Lawrence; Chan, Josephine

doi:10.1111/j.1440-0960.2011.00771.x

Cited by 14 publications

(8 citation statements)

References 10 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results for pamidronate and alendronate are better than those for etidronate, which have been largely negative [99–100]. Interestingly, two cases of DM (without calcinosis) have been reported in adults after administration of zoledronic acid [101–102]. The structural differences among these drugs may explain the difference in efficacy.…”

Section: Treatmentmentioning

confidence: 99%

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

et al. 2014

View full text Add to dashboard Cite

Calcinosis is one of the hallmark sequelae of juvenile dermatomyositis (JDM), and despite recent progress in the therapy of JDM, dystrophic calcification still occurs in approximately one-third of patients. This review discusses our current, albeit limited, understanding of risk factors for the development of calcinosis in JDM, as well as approaches to assessment, and current views on its pathogenesis. Anecdotal approaches to treating calcinosis associated with JDM, including both anti-inflammatory therapies and agents aimed at inhibiting the deposition of calcium hydroxyapatite, are reviewed. An improved understanding of the pathogenesis of calcinosis, the establishment of standardized measurement tools to assess calcinosis, and randomized controlled trials employing more sensitive outcome measures are needed to develop efficacious therapies for this often disabling complication.

show abstract

Section: Treatmentmentioning

confidence: 99%

The Presentation, Assessment, Pathogenesis, and Treatment of Calcinosis in Juvenile Dermatomyositis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Her laboratories confirmed the diagnosis with an extremely elevated creatinine kinase, alanine transaminase, and alkaline phosphatase, along with a positive antinuclear antibody. 9 The second patient was a 65-year-old woman, also on ZA for osteoporosis, presented with widespread erythematous plaques along with proximal muscle weakness and weight loss 5 months after ZA administration. The patient had positive antinuclear and anit-Jo-1 antibodies, elevated AST, alanine transaminase, and creatinine kinase 10 (Table 2 ).…”

Section: Discussionmentioning

confidence: 99%

Zoledronic Acid–Induced Interface Dermatitis

Succaria

Collier

Mahalingam

2015

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Abstract:Zoledronic acid (ZA) is a bisphosphonate given intravenously, most commonly for the treatment of postmenopausal osteoporosis. Increase in usage of ZA because it was FDA-approved has resulted in increasing reports of side effects. For the most part, these are systemic. Cutaneous side effects associated with ZA are infrequent and limited to 2 reports of dermatomyositis to date. In both, patients presented with clinical and laboratory stigmata of dermatomyositis soon after initiation of therapy. In this report, we describe a 62-year-old woman who presented with diffuse, erythematous scaly plaques over the right thigh after 12 hours of infusion of ZA. Histopathologic examination of a skin biopsy from the right thigh revealed patchy scale crust containing neutrophils and inspissated serum, interface change with scattered individually necrotic keratinocytes, and a mild, superficial perivascular lymphocytic infiltrate with scattered eosinophils and pigment incontinence—findings consistent with an interface dermatitis. Given that the patient had no other systemic manifestations or laboratory abnormalities, to the best of our knowledge, ours is the first report of interface dermatitis secondary to ZA with the caveat that longer follow-up is required to definitively exclude the development of drug-induced connective tissue disease.

show abstract

“…Cutaneous adverse skin reactions to zoledronic acid are not frequent (Table 3) [13,[17][18][19][20][21][22][23][24]. Conjunctivitis and hyperhidrosis have more commonly been observed [16].…”

Section: Discussionmentioning

confidence: 99%